Drug Shortage Report for LEVOTHYROXINE SODIUM INJECTION
| Report ID | 173469 |
| Drug Identification Number | 02499916 |
| Brand name | LEVOTHYROXINE SODIUM INJECTION |
| Common or Proper name | LEVOTHYROXINE SODIUM INJECTION |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | LEVOTHYROXINE SODIUM |
| Strength(s) | 40MCG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAMUSCULAR |
| Packaging size | 5 mL |
| ATC code | H03AA |
| ATC description | THYROID PREPARATIONS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2022-12-31 |
| Actual start date | 2022-12-31 |
| Estimated end date | 2023-03-08 |
| Actual end date | 2023-03-08 |
| Shortage status | Resolved |
| Updated date | 2023-03-10 |
| Company comments | Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Levothyroxine Sodium Injection 40 mcg/mL SD Vial 5 mL and 100 mcg/mL SD Vial 5 mL effective December 31, 2022 until March 8, 2023. Please note all current inventory of these products is currently short-dated and expires December 31, 2022. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v7 | 2023-03-10 | French | Compare |
| v6 | 2023-03-10 | English | Compare |
| v5 | 2023-02-15 | French | Compare |
| v4 | 2023-02-15 | English | Compare |
| v3 | 2023-01-01 | English | Compare |
| v2 | 2022-11-03 | French | Compare |
| v1 | 2022-11-03 | English | Compare |
Showing 1 to 7 of 7